Strategy Manager - Emerging Business Lines - 6 Month FTC

Last updated 13 hours ago

About the Role

Reporting to the Global Head of Emerging Business Lines, the Strategy Manager will focus on the development and implementation of the go-to-market strategy for Abcam’s emerging business lines.

The role will sit within the Product Portfolio & Innovation (PPI) group and collaborate closely with different functions (e.g., Commercial Portfolio, Corporate Development, Sales, Marketing, Manufacturing, R&D) to define, execute and track market entry strategies. This is expected to include: identification of new opportunities, customer & market research, development and launch; revenue optimisation (sales channel, marketing mix); market entry, M&A, partnerships and licensing.

The ideal candidate will aspire to be a leader in the life science industry and the role will provide a strong platform for personal growth. Projects will have significant exposure to the executive team and you will interact daily with cross functional experts with backgrounds in top life science companies and professional service organisations.

Note this role is a 6-month fixed term contract.


  • Collaborate with executives, customers, and management to develop, evaluate and deliver creative short, mid and long-term strategies for growth and competitive differentiation
  • Make actionable recommendations based on analysis of market dynamics, financials, growth opportunities and threats
  • Collaborate with consumer insight to generate unique and proprietary market insights e.g., to prioritise customer segments and business opportunities
  • Provide analysis and reports on team projects to ensure milestones and deliverables will be met
  • Support target identification and deal negotiations for M&A activity and with third party partners
  • Develop in-depth knowledge of the market, industry, and potential clients

Where appropriate, the scope of responsibilities can be adjusted to reflect a candidate’s strengths and experiences. More and less senior candidates will be considered if they meet the minimum qualifications.

About you

Our ideal candidate will have a proven track record of strong business impact, either with consulting experience with a top tier consulting firm or practical experience in relevant areas such as Strategy, Marketing and Commercial in the life sciences industry. Your experience will ensure you have deep knowledge in life sciences industry and value chain (e.g., pharmaceuticals, biotechnology, medical devices, healthcare IT). Knowledge or experience in Antibody/Protein Engineering, Synthetic Biology, Biomarkers / Diagnostics, Gene Editing Field, and / or CRISPR-related applications would be beneficial but not essential.

You will be self-motivated and detail-orientated team player and have the ability to multi-task gained from extensive experience in project and program management. You will have distinctive analytical skills (quantitative and qualitative) and excellent communication skills.

You will have an undergraduate degree (or equivalent) ideally in a life sciences subject. A doctorate (PhD) in a life sciences subject and / or a Masters of Business Administration (MBA) would be advantageous but not essential.

About Abcam

Founded in 1998, Abcam PLC was an early pioneer of eCommerce in the life sciences industry.

Over the past 20 years, we have continued to be a disruptive, profitable growth company with an aspiration to be the most influential company for life scientists, supporting research, diagnostic and therapeutic discovery. Abcam is now a global leader in affinity reagents with offices across the US, Europe and Asia. It’s our goal to provide a world-standard in protein research tools, technical support and delivery enabling researchers to make life changing breakthroughs faster.

Abcam is growing at 2x the market rate and delivering exceptional financial returns to shareholders. As a result, Abcam is one of the top 5 most value companies listed on AIM with a market cap value of nearly £3bn. Last year total revenue increased 11.4% on a constant exchange rate basis.

Abcam is now looking to radically accelerate our impact and growth trajectory through the rapid development of new technologies, business models and product offerings “Emerging Business Lines”.

Read more about our corporate strategy in our presentation to the 38th Annual JP Morgan Healthcare Conference and our 2019 Annual Report